Benefits
Blood pressure reduction
At a median dose of 365 mg/day over 12 weeks, magnesium reduces systolic blood pressure by approximately 2.8 mmHg and diastolic by 2.1 mmHg vs placebo. Effects are substantially larger in hypertensive adults already on BP medications and those with low baseline magnesium status, where systolic reductions of 7-8 mmHg are documented. Most useful as an adjunct to lifestyle and pharmaceutical BP management.
Migraine prevention
Oral magnesium has Level B evidence from the American Academy of Neurology / American Headache Society for episodic migraine prevention. At 400-600 mg/day, attack frequency reduces by 22-43% across pooled analyses. The best-evidence trial documented a 41.6% reduction in attack frequency with trimagnesium dicitrate 600 mg/day over 12 weeks (vs 15.8% with placebo). A reasonable first-line preventive.
Sleep onset latency in older adults
Magnesium supplementation reduces sleep onset latency by approximately 17 minutes in older adults with insomnia vs placebo. Total sleep time improvement is modest and not consistently significant across trials. Evidence quality is graded low (trials at moderate-to-high risk of bias), but the effect direction and the underlying NMDA/GABA mechanism are consistent. Glycinate or malate forms preferred.
Muscle function and exercise cramps
Magnesium is essential for muscle contraction-relaxation cycling — it competes with calcium at neuromuscular junctions and is the catalytic cofactor for ATP-dependent muscle energy reactions. Hypomagnesemia exacerbates exercise-induced cramps and impairs endurance. Sweat losses of 4-24 mg/L during heavy training can deplete reserves, particularly in heat-acclimatizing athletes and those on low-carb diets.
Insulin sensitivity and type 2 diabetes risk
Higher magnesium intake is associated with 15-30% reduced relative risk of type 2 diabetes across observational studies. Supplementation in individuals with hypomagnesemia or insulin resistance improves insulin receptor function and glycemic markers (fasting glucose, HOMA-IR). Effect is strongest in deficient individuals; replete adults see smaller benefit. Mechanism: cofactor for tyrosine kinase activity in insulin signaling.
Bone density and osteoporosis risk
Magnesium supports calcium absorption, vitamin D activation (cofactor for both 25- and 1α-hydroxylation), and bone matrix formation. About 60% of body magnesium is stored in bone. Observational data link higher intake to greater bone mineral density and reduced fracture risk; controlled trial evidence is more limited. A reasonable adjunct alongside calcium and vitamin D, not a standalone osteoporosis treatment.
Stress, anxiety, and mood
Magnesium modulates NMDA receptor activity and supports GABAergic neurotransmission — pathways central to stress and anxiety. Improvements in subjective stress and depression scales have been documented at 200-450 mg/day over 4-12 weeks, particularly in adults with low baseline magnesium. Effects are modest and best documented in deficient populations. Glycinate is the form most studied for mood and anxiety.
Cognitive function (L-threonate form specifically)
Magnesium L-threonate (Magtein®) was developed because most magnesium forms cross the blood-brain barrier poorly. At 1.5-2 g/day for 12 weeks in adults aged 50-70 with subjective cognitive impairment, it improves executive function and memory. Effect sizes are modest and replication is limited. The most rigorously tested form for cognitive applications, though the overall evidence base is smaller than for BP or migraine.
Electrolyte support during exercise and heat
Magnesium is one of the four major electrolytes lost through sweat alongside sodium, potassium, and chloride. It's the cofactor for the Na⁺/K⁺-ATPase pump that drives cellular fluid balance. Modern sports hydration formulas typically include 50-100 mg/serving (citrate, malate, or glycinate). Particularly relevant for athletes in heat, low-carb dieters (increased renal excretion), and those on diuretics.
Mechanism of action
Cofactor for 300+ enzymatic reactions
Magnesium is a cofactor for over 300 enzymes including those involved in ATP synthesis, DNA replication, protein synthesis, and glucose metabolism. ATP itself exists predominantly as the Mg-ATP complex in cellular metabolism.
Calcium channel modulation
Acts as a natural calcium channel blocker, regulating calcium influx into smooth muscle cells. This explains BP-lowering effects (vascular relaxation), migraine prophylaxis (cortical neuron stabilization), and muscle relaxation (neuromuscular junction).
NMDA receptor regulation and GABA modulation
Magnesium blocks NMDA receptor channels at resting membrane potential, preventing excessive glutamate excitotoxicity. Also modulates GABA-A receptors. Together these explain neurological effects on sleep, anxiety, and migraine.
Vitamin D activation
Required cofactor for both 25-hydroxylase (liver) and 1α-hydroxylase (kidney) — the enzymes that convert vitamin D to its active form. Magnesium deficiency limits vitamin D efficacy regardless of intake.
Insulin signaling and glucose metabolism
Magnesium phosphorylates the insulin receptor, supports GLUT4 glucose transporter function, and is required for glucokinase activity. Chronic magnesium deficiency impairs insulin sensitivity and contributes to T2D risk.
Clinical trials
Evidence review and dose-response pooled analysis evaluating oral magnesium supplementation for blood pressure outcomes. Trials included various magnesium salts (citrate, oxide, chloride, lactate, others). Median intervention 12 weeks. Published in Hypertension.
2,709 participants across 38 clinical trials (hypertensive and normotensive adults). 12-week median intervention.
Median dose 365 mg elemental magnesium per day reduced systolic blood pressure by 2.81 mmHg and diastolic by 2.05 mmHg vs placebo. Hypertensive patients on BP medications and those with hypomagnesemia showed substantially greater reductions (SBP -7.68 mmHg). Dose-response relationship documented across the 200-500 mg/day range.
Evidence review and pooled analysis of randomized controlled trials evaluating oral magnesium supplementation for sleep quality in older adults with insomnia. Published in BMC Complementary Medicine and Therapies. Trials used various magnesium forms; outcomes assessed by validated sleep questionnaires (PSQI, ISI) and actigraphy.
151 older adults with insomnia across 3 clinical trials. 4-8 week supplementation periods.
Magnesium supplementation reduced sleep onset latency by 17.36 minutes vs placebo (95% CI -27.27 to -7.44). Total sleep time improved by 16 minutes (not statistically significant). Evidence quality graded low due to moderate-to-high risk of bias in included trials, but effect direction is consistent with the mechanistic plausibility.
Randomized double-blind placebo-controlled trial of magnesium L-threonate (Magtein®) for cognitive function in adults aged 50-70 with subjective cognitive impairment. Cognitive function assessed via a battery measuring executive function, memory, attention, and processing speed.
Adults aged 50-70 with subjective cognitive impairment. 12-week supplementation.
1.5-2 g/day Magtein® significantly improved executive function and memory vs placebo. Effects were modest in magnitude but reproducible across domains. The trial established proof-of-concept that L-threonate's ability to cross the blood-brain barrier translates to measurable cognitive outcomes — a distinguishing feature of this magnesium form.
Randomized double-blind placebo-controlled trial of high-dose magnesium for migraine prevention. Used trimagnesium dicitrate at high oral dose for 12 weeks. Outcomes: migraine attack frequency, intensity, duration, and medication use. Foundational trial for the AAN/AHS Level B recommendation.
81 patients with episodic migraine (without aura). 12-week intervention.
Trimagnesium dicitrate 600 mg/day reduced migraine attack frequency by 41.6% vs 15.8% with placebo. Effect emerged over the 12-week protocol rather than acutely. Combined with subsequent trials and pooled analyses, this established oral magnesium as a Level B recommendation from the American Headache Society and American Academy of Neurology for episodic migraine prevention.
Open-label randomized controlled trial of magnesium chloride for mild-to-moderate depression in adults. Outcomes assessed via PHQ-9 (depression) and GAD-7 (anxiety) validated scales. 6-week intervention period with crossover design.
126 adults with mild-to-moderate depression. 6-week intervention.
Magnesium chloride at 248 mg/day reduced PHQ-9 depression scores by 6.0 points vs baseline and 4.2 points vs control. GAD-7 anxiety scores also improved. Effects emerged within 2 weeks and were sustained through the 6-week protocol. Open-label design limits causal interpretation but effect size is clinically meaningful in this population.
Randomized placebo-controlled trial of magnesium L-threonate (Magtein®) for sleep quality. Outcomes measured by both objective methods (actigraphy — wrist-worn movement sensors) and subjective methods (Pittsburgh Sleep Quality Index, or PSQI).
Healthy adults with sleep complaints. Multi-week supplementation period.
Magtein® at 1 g/day improved both objective (actigraphy) and subjective (PSQI) sleep quality vs placebo. Effect sizes were smaller than for the cognition outcomes from the same form. Provides evidence that L-threonate's CNS penetration translates to sleep benefits alongside its cognitive applications, though at lower magnitude than dedicated sleep-focused forms like glycinate.